Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies

IMPRESS (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) I and II examined the clinical efficacy and safety of collagenase Clostridium histolyticum intralesional injections in subjects with Peyronie disease. Co-primary outcomes in these identical phase 3 randomized,...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of urology Vol. 190; no. 1; p. 199
Main Authors:	Gelbard, Martin, Goldstein, Irwin, Hellstrom, Wayne J G, McMahon, Chris G, Smith, Ted, Tursi, James, Jones, Nigel, Kaufman, Gregory J, Carson, 3rd, Culley C
Format:	Journal Article
Language:	English
Published:	United States 01.07.2013
Subjects:	Adult Clinical Trials, Phase III as Topic Clostridium histolyticum - enzymology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Follow-Up Studies Humans Injections, Intralesional Male Maximum Tolerated Dose Microbial Collagenase - administration & dosage Middle Aged Patient Safety Patient Satisfaction Penile Induration - diagnosis Penile Induration - drug therapy Prospective Studies Randomized Controlled Trials as Topic Risk Assessment Severity of Illness Index Treatment Outcome
ISSN:	1527-3792, 1527-3792
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!